AttendMe Owl Logo
AttendMe
Evidence Evolution
Obstetrics & GynecologyObstetrics & Gynecology

How This Evidence Evolved

Gestational Diabetes Screening

From O'Sullivan criteria through HAPO continuous risk to the one-step vs two-step debate

26.2

Timeline

Signal

Early observations and pilot data that first suggested a new direction

Proof

Landmark RCTs and pivotal trials that established the evidence base

HAPO (2008) tested 25,505 pregnant women at 15 centers in nine countries with a 75-g oral glucose tolerance test at 24–32 weeks. The analysis included 23,316 participants whose data remained blinded under prespecified glucose limits. It found continuous associations between maternal glucose and several pregnancy outcomes, with no obvious thresholds at which risks increased. Associations were especially clear for birth weight and cord C-peptide above the 90th percentile. These findings informed IADPSG thresholds; they did not establish a linear relation for every endpoint or a glucose level below which all risk was absent.
Extension

Follow-up studies, subgroup analyses, and real-world validation

IADPSG used HAPO associations to select diagnostic glucose thresholds corresponding to outcome odds of 1.75 relative to mean glucose values. ACHOIS found fewer serious perinatal complications with dietary advice, glucose monitoring, and insulin as needed (1% versus 4%), while caesarean rates were similar. In the Landon trial, treatment of mild GDM did not significantly reduce the primary neonatal composite, but reduced fetal overgrowth, shoulder dystocia, caesarean delivery, and hypertensive disorders. The screening criteria and the benefits of treating diagnosed disease are distinct evidence questions.
Guidelines

Integration into clinical practice guidelines and recommendations

A 2019 review reports one-step 75-g OGTT using IADPSG criteria in low-risk pregnant women under WHO 2013, FIGO 2015 and Endocrine Society 2013 guidance. The thresholds are fasting ≥5.1, 1 h ≥10.0 and 2 h ≥8.5 mmol/L. It reports ACOG 2018 two-step screening. An independent 2013 panel recommended continuing 50-g screening followed, if abnormal, by a 100-g OGTT; its report is not NIH or federal policy. At least one IADPSG threshold must be equaled or exceeded. ScreenR2GDM diagnosed GDM in 16.5% versus 8.5%, without significant primary maternal or perinatal outcome differences. Diagnostic yield and clinical benefit differ.
IADPSG Consensus Panel

75-g OGTT at 24–28 weeks if diabetes/GDM not already diagnosed; ≥1 threshold: fasting ≥5.1, 1h ≥10.0, 2h ≥8.5 mmol/L.

2019 guideline review: FIGO 2015

For low-risk pregnancy: FIGO 2015 recommends one-step 75-g OGTT with IADPSG criteria.

Now

Current standard of care and ongoing research directions

ScreenR2GDM is complete: 23,792 women underwent randomization to one-step or two-step screening. One-step screening produced more GDM diagnoses (16.5% vs 8.5%), without significant differences in primary maternal and perinatal complication outcomes. Adherence differed (66% vs 92%). IADPSG recommends early testing for overt diabetes in populations with high type 2 diabetes prevalence, and a 75-g OGTT at 24–28 weeks in women not already diagnosed. Its 2010 report found insufficient evidence for routinely diagnosing and treating GDM before that window and advised postpartum glucose testing after GDM or overt diabetes in pregnancy. Optimal screening strategy and long-term follow-up remain clinical questions.

Landmark Trials in This Story

O'Sullivan 19641964Landmark

CRITERIA FOR THE ORAL GLUCOSE TOLERANCE TEST IN PREGNANCY.

Oral glucose-tolerance criteria in pregnancy

Diabetes
HAPO2008Landmark

Hyperglycemia and adverse pregnancy outcomes

Birthweight, caesarean, neonatal glucose, cord C-peptide

New England journal of medicineProspective observational (blinded)N=23,316
ACHOIS2005Landmark

Effect of treatment of gestational diabetes mellitus on pregnancy outcomes

Serious perinatal complications (composite)

New England journal of medicineRCT
Landon 20092009

A multicenter, randomized trial of treatment for mild gestational diabetes.

Primary neonatal composite: treatment 32.4% vs usual care 37.0% (P=0.14; no significant reduction)

The New England journal of medicineRandomized trial of treatment versus usual care for mild gestational diabetesN=958
IADPSG Criteria2010Landmark

International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy

Diagnostic thresholds for GDM

Diabetes careConsensus recommendation based on HAPO data
Landon mild GDM2009

A multicenter, randomized trial of treatment for mild gestational diabetes.

Primary neonatal composite: treatment 32.4% vs usual care 37.0% (P=0.14)

The New England journal of medicineRandomized controlled trialN=958
ScreenR2GDM2021

A Pragmatic, Randomized Clinical Trial of Gestational Diabetes Screening.

GDM diagnosis: one-step 16.5% vs two-step 8.5% (RR 1.94, 97.5% CI 1.79–2.11)

The New England journal of medicinePragmatic randomized screening trialN=23,792
Independent 2013 GDM consensus panel2013

NIH consensus development conference: diagnosing gestational diabetes mellitus.

The 2013 independent panel recommended continuing 50-g screening followed by a 100-g OGTT after an abnormal screen; not NIH or federal policy.

NIH consensus and state-of-the-science statementsIndependent consensus panel statement

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

What is the difference between one-step and two-step GDM screening?+
One-step screening uses a fasting 75-g oral glucose test. ScreenR2GDM diagnosed GDM in 16.5% with one-step versus 8.5% with two-step screening, but found no significant differences in its primary maternal and perinatal complication outcomes.
Does treating gestational diabetes improve outcomes?+
Treatment can improve outcomes, but the benefits differ by endpoint. ACHOIS reduced serious perinatal complications from 4% to 1%, without lowering caesarean rates. Landon found no significant primary composite benefit in mild GDM, but lower fetal overgrowth, shoulder dystocia, caesarean delivery, and hypertensive disorders. Both trials used dietary intervention, glucose monitoring, and insulin when needed.
Why did the HAPO study change GDM diagnosis?+
HAPO found continuous associations between maternal glucose and several adverse pregnancy outcomes, without obvious thresholds at which risk increased. IADPSG then selected diagnostic thresholds using an odds ratio of 1.75 relative to mean glucose values, after also considering 1.5 and 2.0. This made a practical diagnostic boundary within a continuous risk relationship.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026